Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions
CM-CS1 T-cell infusion
Biological
Lead sponsor
Celyad Oncology SA
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions
Rasburicase (SR29142), Allopurinol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more
Active, not recruiting Phase 2 Interventional

MMRC Horizon One: RRMM (MMRC-099)

NCT06171685
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Teclistamab Monotherapy, Teclistamab
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
daclizumab, therapeutic allogeneic lymphocytes, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Healthy
Interventions
Nemtabrutinib, Diltiazem
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Terminated Not applicable Interventional Accepts healthy volunteers

Home Test for Measuring Plasma P-tau217 in Alzheimer's Disease

NCT06622135
Conditions
Alzheimer Disease, Healthy Subjects
Interventions
Tasso Lancet Device
Device
Lead sponsor
Insight Research Institute
Other
Eligibility
55 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Chicago, Illinois • Flint, Michigan
Conditions
Multiple Myeloma, Auto Stem Cell Transplant
Interventions
Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic, Myelodysplastic Syndromes, Multiple Myeloma, Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
AMD3100, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Healthy Volunteers
Interventions
OLT maneuver, Sham OLT
Other
Lead sponsor
Kansas City University of Medicine and Biosciences
Other
Eligibility
20 Years to 40 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Waldenström Macroglobulinemia
Interventions
vorinostat, rituximab, ifosfamide, carboplatin, etoposide, pharmacological study, laboratory biomarker analysis, gene expression analysis
Drug · Biological · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Malignant Solid Neoplasm, Chronic Lymphocytic Leukemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma
Interventions
American Ginseng, Placebo Administration, Questionnaire Administration
Dietary Supplement · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
15
States / cities
Albert Lea, Minnesota • Bemidji, Minnesota • Brainerd, Minnesota + 12 more
Conditions
Colorectal Cancer Stage IV, Colorectal Cancer Metastatic, Colorectal Cancer, Genetics of, Appendix Cancer
Interventions
prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma
Interventions
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 78 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more
Conditions
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
Interventions
Sargramostim, BB-MPI-03, Montanide
Drug
Lead sponsor
Benovus Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Fairfax, Virginia
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
alisertib, rituximab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Columbus, Ohio
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, cyclophosphamide, lenalidomide, laboratory biomarker analysis, dexamethasone, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Baltimore, Maryland • St Louis, Missouri + 1 more
Conditions
Acute Myeloid Leukemia, Myelodysplasia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Multiple Myeloma, Lymphoma, Large-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, T-Cell, Peripheral, T-NK Cell Lymphoma, Hodgkin Disease
Interventions
umbilical cord stem cells
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Non Follicular Indolent Non-Hodgkin Lymphoma
Interventions
Umbralisib
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Hackensack, New Jersey + 1 more
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, cyclophosphamide, melphalan, peripheral blood stem cell transplantation, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Cardio-Pulmonary Bypass
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
1 Day to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib, Dexamethesone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
2
States / cities
Boston, Massachusetts